الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 182 |  |  |
| | | from | 182 | | |
Abstract
HCC is the most common primary malignancy of the liver. chronic
liver disease due to HBV or HCV accounts for the majority of HCC cases
and thus, highly amenable to preventive measures.
Cancer, like any disease, is a pathologic biological process. Drugs are
designed to interfere with the pathologic process and should therefore also
be validated using a functional screening method directed at these processes.
Screening for cancers at an appropriate time and also evaluating results is
also very important.
The incidence of hepatocellular carcinoma is increasing worldwide.
TACE slows tumor progression and improves survival by combining the
effect of targeted chemotherapy with that of ischemic necrosis induced by
arterial embolization. Conventional approaches for treatment response
assessment, such as RECIST which is based on tumor size reduction, are
suboptimal in predicting HCC patients‘ outcome treated with TACE.
Since anticancer efficacy of TACE is assessed by viable rather than global tumor size reduction, EASL and m RECIST, which quantify the
viable portion of tumor by contrast-enhanced CT, have been proposed.
Volumetric image analysis allows an accurate, precise, sensitive, and
medically valuable assessment of tumor response. It also helps in identifying
possible outcomes such disease progression or complete response as per
RECIST.
So, a prospective comparative study was carried out to measure the
role of multi-detector computed tomography in tumor response evaluation of
conventional Trans-arterial chemoembolization in hepatocellular carcinoma.